Neurocrine Biosciences Inc (NBIX.O): 2Q26 Model Update

First-page research excerpt

Action |

31 Jul 2026 13:01:35 ET │ 12 pages

Neurocrine Biosciences Inc (NBIX.O)

2Q26 Model Update

CITI'S TAKE

We have updated our model to reflect 2Q26 earnings. Please see our

thoughts on the strong quarter here — Neurocrine Biosciences Inc (NBIX.O)

- Crenessity Growth Continues to Outpace Expectations While Ingrezza

Guide Raise Reinforces Durable VMAT2 Demand. Our TP increases to $249

from $246 following changes to both our Ingrezza and Crenessity models to

reflect higher expected 2026 revenue, offset slightly by higher OpEx

following the Soleno acquisition. Our Ingrezza estimate for 2026 now

increases to $2.85B from the previous guidance range of $2.7B$2.8B. Reiterate Buy.

n

Buy / High Risk

Price (30 Jul 26 16:00)

US$185.50

Target price

US$249.00↑

from US$246.00

Expected share price return

34.2%

Expected dividend yield

0.0%

Expected total return

34.2%

Market Cap

US$18,652M

Price Performance

(RIC: NBIX.O, BB: NBIX US)

Yigal Nochomovitz, Ph.D. AC

EPS (US$)

Q1

Q2

Q3

Q4

FY

FC Cons

VA Cons

2025A

0.70A

1.65A

2.47A

2.03A

6.79A

4.67A

6.39A

2026E

2.44A

1.91A

3.31E

3.54E

11.22E

7.43E

8.87E

Previous

2.44A

2.81E

3.77E

3.40E

12.42E

na

2027E

na

10.70E

10.39E

11.11E

Previous

na

11.13E

na

2028E

na

14.58E

13.27E

14.26E

Previous

na

14.59E

na

Joohwan Kim

Caroline DePaul

Source: Company Reports and dataCentral, Citi Research. FC Cons: First Call Consensus. VA Cons: Visible Alpha Consensus.

Click here for Visible Alpha consensus data